Emyria (ASX:EMD) introduced the Empax global partnership program to enable international drug sponsors to access its established clinical delivery infrastructure.

The world-first service will provide a structured pathway for drug sponsors and clinical research organisations (CROs) to deliver complex treatment protocols through Emyria’s Empax network, supporting clinical trial execution and post-approval commercial rollout.

https://smallcaps.com.au/article/emyria-launches-empax-global-partnership-platform-targeting-international-drug-sponsors